Cargando…
AB004. New technology and therapy for bladder cancer
Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundam...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842617/ http://dx.doi.org/10.21037/tau.2016.s004 |
_version_ | 1782428556047941632 |
---|---|
author | Meng, Max |
author_facet | Meng, Max |
author_sort | Meng, Max |
collection | PubMed |
description | Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundamentally changed over the past decade. In this lecture, we will discuss (I) new technology in the detection and monitoring of non-invasive disease (blue-light and narrow band imaging); (II) the role of lymphadenectomy at the time of cystectomy; (III) a novel risk stratification tool predicting prognosis after cystectomy; and (IV) systemic therapies and clinical trials for advanced and refractory disease. |
format | Online Article Text |
id | pubmed-4842617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-48426172016-05-09 AB004. New technology and therapy for bladder cancer Meng, Max Transl Androl Urol Plenary Session Urothelial carcinoma of the bladder remains a significant oncologic problem throughout the world and is a source of both morbidity and mortality. Despite advances in the understanding of disease and recent molecular data from The Cancer Genome Atlas, the clinical management of disease has not fundamentally changed over the past decade. In this lecture, we will discuss (I) new technology in the detection and monitoring of non-invasive disease (blue-light and narrow band imaging); (II) the role of lymphadenectomy at the time of cystectomy; (III) a novel risk stratification tool predicting prognosis after cystectomy; and (IV) systemic therapies and clinical trials for advanced and refractory disease. AME Publishing Company 2016-04 /pmc/articles/PMC4842617/ http://dx.doi.org/10.21037/tau.2016.s004 Text en 2016 Translational Andrology and Urology. All rights reserved. |
spellingShingle | Plenary Session Meng, Max AB004. New technology and therapy for bladder cancer |
title | AB004. New technology and therapy for bladder cancer |
title_full | AB004. New technology and therapy for bladder cancer |
title_fullStr | AB004. New technology and therapy for bladder cancer |
title_full_unstemmed | AB004. New technology and therapy for bladder cancer |
title_short | AB004. New technology and therapy for bladder cancer |
title_sort | ab004. new technology and therapy for bladder cancer |
topic | Plenary Session |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4842617/ http://dx.doi.org/10.21037/tau.2016.s004 |
work_keys_str_mv | AT mengmax ab004newtechnologyandtherapyforbladdercancer |